Antimicrobial Peptides: Delivery by Dendritic Mesoporous Silica Nanoparticles Enhances the Antimicrobial Activity of a Napsin‐Derived Peptide Against Intracellular <i>Mycobacterium tuberculosis</i> (Adv. Healthcare Mater. 14/2021)

Beitzinger, Bastian; Gerbl, Fabian; Vomhof, Thomas; Schmid, Roman; Noschka, Reiner; Rodríguez, Armando A.; Wiese, Sebastian; Weidinger, Gilbert; Ständker, Ludger; Walther, Paul; Michaelis, Jens; Lindén, Mika; Stenger, Steffen

doi:10.1002/adhm.202170066

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSNs can be used as carriers for the delivery of silver nanoparticles to target sites because they have very high bactericidal potency. A 2D hexagonal MSN containing silver bromide also showed good antimycobacterial activity [228].…”

Section: Silica Nanoparticlesmentioning

confidence: 99%

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair,

Greeny,

Nandan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. Graphical Abstract

show abstract

Section: Silica Nanoparticlesmentioning

confidence: 99%